Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01275365 · ClinicalTrials.gov registry record · Phase 3

Optimizing Protein Intake in Older Americans With Mobility Limitations

A Phase 3 study of Mobility Limitation, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 3
Development phase
92
Enrollment target
1
Study location

NCT01275365 is a Phase 3 study of Mobility Limitation that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 92 participants, below the 253-participant average among 28 other Mobility Limitation trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01275365, a Phase 3 study of Mobility Limitation, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 3
Development phase
92 participants
Enrollment target
1
Study location

Study Summary

This will be a randomized, placebo-controlled, parallel group, double blind, clinical trial in community dwelling, older men, 65 years of age or older, who have mobility limitation and low protein intake. The study will have a 2 X 2 factorial design, which will allow us to investigate the effects of dietary protein intake and testosterone separately and together.

Conditions Studied

Interventions

  • DRUG Testosterone enanthate

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2011-05
Est. Completion 2017-01-19
Phase Phase 3

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT01275365

The ClinicalTrials.gov registry entry for NCT01275365 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 253-participant average among 28 other Mobility Limitation trials with a reported enrollment target (64% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mobility Limitation appearing as the primary indexed condition, and to 1 intervention - of which Testosterone enanthate is the first listed.

NCT01275365 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01275365 about?

NCT01275365 is a clinical study titled "Optimizing Protein Intake in Older Americans With Mobility Limitations". This will be a randomized, placebo-controlled, parallel group, double blind, clinical trial in community dwelling, older men, 65 years of age or older, who have mobility limitation and low protein intake. The study will have a 2 X 2 factorial design, which will allow us to investigate the effects of...

What is the current status of trial NCT01275365?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2011-05. Estimated completion is 2017-01-19.

What conditions does trial NCT01275365 study?

This clinical trial studies the following conditions: Mobility Limitation.

What interventions are being tested in trial NCT01275365?

The interventions under investigation include: Testosterone enanthate (DRUG).

Who is sponsoring clinical trial NCT01275365?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01275365 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mobility Limitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.